Navigation Links
Synthetic Biologics to Present at the 2013 BIO CEO & Investor Conference
Date:2/5/2013

ROCKVILLE, Md., Feb. 5, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that its Chief Executive Officer, Jeffrey Riley , will present at the 2013 BIO CEO & Investor Conference. The conference will be held February 11-12, 2013 at the Waldorf-Astoria Hotel in New York City. Mr. Riley is scheduled to present on Tuesday, February 12, 2013 at 11:00 a.m. (Eastern Time).

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the web at http://www.veracast.com/webcasts/bio/ceoinvestor2013/06212103.cfm. After the presentation, a replay will be archived and accessible for 30 days at the same website.

Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne , and its EVP, Research & Development, John Monahan , Ph.D., will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

About Synthetic Biologics, Inc.

Synthetic Biologics is a biotechnology company focused on the development of product candidates for serious infections and diseases. Synthetic Biologics is developing a biologic for the prevention of C. difficile infection, and a series of monoclonal antibodies for the treatment of serious infectious diseases, including pertussis and Acinetobacter. The Company is also developing a synthetic DNA-based therapy for the treatment of pulmonary arterial hypertension. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and is designing a clinical development pathway for the treatment of amyotrophic lateral sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.

 

 


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. New synthetic biology technique boosts microbial production of diesel fuel
2. UC Santa Barbara researchers develop synthetic platelets
3. Synthetic diamond steps closer to next generation of high performance electrochemical applications
4. Synthetic Biology Scorecard finds federal agencies responding to bioethics report
5. Collagen-seeking synthetic protein could lead doctors to tumor locations
6. Synthetic biofilter wins through to the top Sweet 16 in Boston
7. Nottingham part of £20m investment for UK synthetic biology
8. Microchoreography: Researchers use synthetic molecule to guide cellular dance
9. Synthetic fuel could eliminate US need for crude oil
10. New report finds increase in media coverage of synthetic biology
11. Synthetic and biological nanoparticles combined to produce new metamaterials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2016)... 18, 2016  Extenua Inc., a pioneering developer ... use and access of ubiquitous on-premise and cloud ... American Cyber.  ... transformational C4ISR and Cyber initiatives in support of ... proven technology solutions," said Steve Visconti , ...
(Date:1/11/2016)... Synaptics Incorporated (NASDAQ: SYNA ), the ... its ClearPad ® TouchView ™ 4300 touch ... categories in the 8 th Annual Mobile Excellence ... The Synaptics ® TDDI solution enables faster time-to-market, ... devices, brighter displays and borderless designs. ...
(Date:1/7/2016)... -- This BCC Research report studies the global as ... identifying newer markets and exploring the expansion of the ... Includes forecast from 2015 to 2020. Use ... the expansion of the present application market for various ... technology, determine its current market size, and estimate the ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... SHELTON, Conn. , Feb. 8, 2016  NanoViricides, Inc. (NYSE ... that its CEO, Eugene Seymour , MD, MPH, will present ... 5:30PM at the Waldorf-Astoria Hotel in New York City ... presentation will be in the Windsor Room at 5:30PM EST. Registered ... New York City . --> ...
(Date:2/8/2016)... --> --> ... Point-Of-Care (POC) molecular diagnostics company, today announces that it has ... to be launched on the Company,s io® platform. By meeting ... is now cleared for sale within the European Union. ... the io® CT test signals a new era in ultra-rapid ...
(Date:2/5/2016)... , Feb. 5, 2016 ATCC, the premier ... to assist the medical and life science researchers that ... Virus infection.   CDC website . ... Zika virus is a single-stranded RNA virus of ... West Nile, Dengue and Chikungunya Viruses. Zika virus is ...
(Date:2/5/2016)... 5, 2016 Amarantus BioScience Holdings, ... focused on developing products for Regenerative Medicine, Neurology and ... Disease Designation (RPDD) from the US Food and Drug ... MANF was previously granted orphan drug designation (ODD) by ... Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), ...
Breaking Biology Technology: